Trials / Terminated
TerminatedNCT00454701
Assessment and Tracking of Long-term Alefacept Safety
Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,897 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
Detailed description
There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alefacept exposure | Observational |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2007-04-02
- Last updated
- 2013-12-11
Locations
268 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00454701. Inclusion in this directory is not an endorsement.